Dr. Roland Griffiths is a pioneer in psychopharmacology research, having worked for over 40 years with mood-altering substances. Nearly two decades ago, Dr. Griffiths created the psilocybin research program at Johns Hopkins University.
Most recently his research demonstrated that high-dose synthetic psilocybin, when administered in a safe and clinical setting under the guidance of a team of professionals, was able to have a lasting effect on depression and anxiety in patients with life-threatening cancer mediated through mystical experiences that have a phenomenology and psychometric pattern that corresponds to the same sort of religious or mystical experiences documented throughout human history.
In addition to this most recent research, however, Dr. Griffiths has also done research on: the effects it can have on the so-called personality domain of openness, its effects in beginning and long-term meditators, and the effects it has on enhancing smoking cessation. He’s been a part of brain imaging studies and explored its pharmacological and neural mechanisms of action and conducted surveys on so-called “bad trips”, as well as looked at drug interactions.
This was a dense one, thank god for notes!
An amazing Q&A with the one and only Dom D’Agostino.
Dom is an assistant professor in the Department of Molecular Pharmacology and Physiology at the University of South Florida Morsani College of Medicine, and a senior research scientist at the Institute for Human and Machine Cognition (IHMC) — which is mentioned in the current issue of Outside Magazine (on which there’s a clown who looks a lot like me).
Much of Dom’s work is related to metabolic therapies and nutritional strategies for peak performance and resilience in extreme environments. Dom’s research is supported by the Office of Naval Research (ONR), Department of Defense (DoD), and other private organizations and foundations.
Dr. Ruth Patterson, a professor in the UC San Diego Department of Family Medicine and Public Health as well as Associate Director of Population Sciences and leader of the Cancer Prevention program at Moores Cancer Center at UC San Diego Health. If you enjoyed my last episode with Dr. Satchin Panda, I have good news! This will also be a great episode for you, since we talk about some similar ideas, but focus more on the human side of things, especially when it comes to time-restricted eating, since Dr. Patterson does primarily clinical research. In this 45-minute podcast, we talk about… The importance of time-restricted eating as a practical public health intervention, mostly for it’s ease of implementation, that may have a widespread impact on disease risk. Why you should probably make sure your time-restricted eating window occurs earlier in the day, rather than later. How the first 5% drop in weight loss can have disproportionately large effects on the metabolic factors associated with breast cancer risk when compared with subsequent weight loss. The association of longer fasting durations beginning earlier in the evening and improved sleep in humans, as well as spontaneous physical activity in their day-to-day lives. The relationship between metabolism and breast cancer risk. The effect of lifestyle factors, such as obesity, physical activity, what and even when you eat, whether or not you smoke tobacco… and how even modest changes, such as consuming food earlier in the day and only during an 11-hour window, can decrease breast cancer risk and recurrence by as much as 36%. The importance of starting your fast earlier in the evening, and how an earlier eating window has been shown to correlate to reductions in inflammatory markers.